+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Forecast 2024-2030- Product Image
Global Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Forecast 2024-2030- Product Image
Sale

Global Sarcoma Drugs Market by Indication (Angiosarcoma, Chondrosarcoma, Dermatofibrosarcoma Protuberans), Drugs (Chemotherapy Drugs, Immunotherapy Drugs, Targeted Drug Therapy), Sales Channel, End-User - Forecast 2024-2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5889758
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sarcoma Drugs Market size was estimated at USD 1.54 billion in 2023, USD 1.66 billion in 2024, and is expected to grow at a CAGR of 8.10% to reach USD 2.66 billion by 2030.

Sarcoma drugs are a class of medicinal products specifically designed to treat sarcomas, a rare and heterogeneous group of malignant tumors that arise from mesenchymal tissues such as bone, cartilage, fat, muscle, vascular, or hematopoietic cells. Increasing incidence and prevalence of sarcoma worldwide contribute to the rising demand for effective treatment options. Government initiatives supporting cancer research programs financially enable researchers to explore new treatment avenues for rare malignancies such as soft tissue or bone sarcomas. The high cost of developing novel therapies and the subsequent financial burden on healthcare systems can serve as a barrier to widespread adoption.

Advancements in research have led to a better understanding of tumor biology and genetics associated with different forms of sarcomas. This knowledge facilitates the development of novel targeted therapies that can precisely attack cancer cells without causing significant harm to healthy tissue. Coupled with ongoing clinical trials investigating innovative approaches such as immunotherapy or gene therapy for treating sarcomas, it further enhances the potential opportunities in this market space.

Regional Insights

The Americas have an advanced sarcoma drugs market due to its well-developed healthcare infrastructure, high awareness about cancer treatment options, and a robust pipeline of investigational drugs. Major pharmaceutical companies are headquartered in the U.S. and have a strong presence in this market. Furthermore, collaboration between government agencies and private firms has resulted in accelerated drug approvals by the U.S. Food and Drug Administration (FDA) and Health Canada. Asia is an emerging market for sarcoma drugs driven by the need for effective drugs to treat the increasing prevalence of soft tissue sarcomas (STS) among its large population base.

Countries such as China, India, Japan, South Korea, and Australia are experiencing a rapid increase in R&D for new cancer therapies. Technological advancements, coupled with growing awareness about early diagnosis, have propelled the demand for targeted therapies in this region. Europe showcases a mature market for sarcoma drugs with established players and a strong regulatory framework by the European Medicines Agency (EMA), ensuring that only high-quality medicines reach patients. Furthermore, multiple ongoing clinical trials, collaborations, and partnerships between European pharmaceutical companies and academic research institutions have led to a robust pipeline of investigational drugs in various phases of development.

Market Trends by Segment

  • Indication: High incidence rates of leiomyosarcoma encouraging new drug development
  • Drugs: Adoption of targeted sarcoma drugs for more tailored treatment based on individual genetic mutations
  • Sales Channel: Emerging preference for online sales channel driven by their convenience for home delivery services of prescription medications
  • End-User: Wide range of drug options to cater to various types and stages of sarcoma patients in hospitals & clinics

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment

Sumitomo Pharma Oncology, Inc. has obtained orphan drug designation from the U.S. Food and Drug Administration (FDA) for TP-1287, an oral CDK9 inhibitor. This designation is for the treatment of Ewing sarcoma, a rare pediatric disease that primarily affects children and teenagers. Additionally, TP-1287 has received a rare pediatric disease designation from the FDA, as it is a serious and life-threatening disease. Currently, TP-1287 is undergoing evaluation in a phase 1, first-in-human study for advanced metastatic and progressive solid tumors in the United States.

FDA approves atezolizumab for alveolar soft part sarcoma in pediatric patients

The US Food and Drug Administration (FDA) has granted approval for the use of atezolizumab in the treatment of unresectable and metastatic alveolar soft part sarcoma (ASPS) in patients aged two years and older. ASPS is a type of soft tissue cancer that primarily affects the leg but can potentially spread to other areas, such as the neck, head, and arms.

US FDA grants Orphan Drug status to Avacta’s drug for soft tissue sarcoma

The US Food and Drug Administration (FDA) has granted Avacta Group's lead drug candidate, AVA6000, Orphan Drug Designation (ODD) for the therapy of soft tissue sarcoma. AVA6000 is an updated version of the generic chemotherapy drug doxorubicin, incorporating pre|CISION technology. This innovative technology enables AVA6000 to specifically target tumors while sparing healthy tissues.

Key Company Profiles

The report delves into recent significant developments in the Sarcoma Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AgonOx, Amneal Pharmaceuticals LLC, Aurobindo Pharma Limited, Avacta Life Sciences Limited, Baxter International Inc., Bayer AG, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Fresenius SE & Co. KGaA, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Ipsen Pharma, Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sumitomo Pharma Co., Ltd., Sun Pharmaceutical Industries Limited, TRACON Pharmaceuticals, Inc., and Viatris Inc.

This research report offers invaluable insights into various crucial aspects of the Sarcoma Drugs Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of sarcoma and the need for effective treatment options
5.1.1.2. Government initiatives encouraging the treatment of sarcoma
5.1.1.3. Favorable government approvals for improved sarcoma drugs
5.1.2. Restraints
5.1.2.1. Limited reimbursements available for sarcoma
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for advanced and new sarcoma drugs
5.1.3.2. Improvements in targeted and immunotherapy approaches for sarcoma
5.1.4. Challenges
5.1.4.1. Issues associated with drug resistance in sarcomas
5.2. Market Segmentation Analysis
5.2.1. Indication: High incidence rates of leiomyosarcoma encouraging new drug development
5.2.2. Drugs: Adoption of targeted sarcoma drugs for more tailored treatment based on individual genetic mutations
5.2.3. Sales Channel: Emerging preference for online sales channel driven by their convenience for home delivery services of prescription medications
5.2.4. End-User: Wide range of drug options to cater to various types and stages of sarcoma patients in hospitals & clinics
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Sarcoma Drugs Market, by Indication
6.1. Introduction
6.2. Angiosarcoma
6.3. Chondrosarcoma
6.4. Dermatofibrosarcoma Protuberans
6.5. Epithelioid Sarcoma
6.6. Kaposi's Sarcoma
6.7. Leiomyosarcoma
6.8. Liposarcoma
6.9. Osteosarcoma
6.10. Soft Tissue Sarcoma
7. Sarcoma Drugs Market, by Drugs
7.1. Introduction
7.2. Chemotherapy Drugs
7.3. Immunotherapy Drugs
7.4. Targeted Drug Therapy
8. Sarcoma Drugs Market, by Sales Channel
8.1. Introduction
8.2. Offline
8.3. Online
9. Sarcoma Drugs Market, by End-User
9.1. Introduction
9.2. Cancer Research Center
9.3. Homecare
9.4. Hospital & clinics
10. Americas Sarcoma Drugs Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Sarcoma Drugs Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Sarcoma Drugs Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. Market Share Analysis, 2023
13.2. FPNV Positioning Matrix, 2023
13.3. Competitive Scenario Analysis
13.3.1. Sumitomo Pharma Oncology receives orphan drug designation for Ewing sarcoma treatment
13.3.2. FDA approves atezolizumab for alveolar soft part sarcoma in pediatric patients
13.3.3. US FDA grants Orphan Drug status to Avacta’s drug for soft tissue sarcoma
13.4. Strategy Analysis & Recommendation
14. Competitive Portfolio
14.1. Key Company Profiles
14.2. Key Product Portfolio
List of Figures
FIGURE 1. SARCOMA DRUGS MARKET RESEARCH PROCESS
FIGURE 2. SARCOMA DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SARCOMA DRUGS MARKET DYNAMICS
FIGURE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
FIGURE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2030 (%)
FIGURE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. SARCOMA DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 24. SARCOMA DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. SARCOMA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL SARCOMA DRUGS MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL SARCOMA DRUGS MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL SARCOMA DRUGS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ANGIOSARCOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHONDROSARCOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DERMATOFIBROSARCOMA PROTUBERANS, BY REGION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DERMATOFIBROSARCOMA PROTUBERANS, BY REGION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EPITHELIOID SARCOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL SARCOMA DRUGS MARKET SIZE, BY EPITHELIOID SARCOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI'S SARCOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL SARCOMA DRUGS MARKET SIZE, BY KAPOSI'S SARCOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 20. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LEIOMYOSARCOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 21. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 22. GLOBAL SARCOMA DRUGS MARKET SIZE, BY LIPOSARCOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 23. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 24. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OSTEOSARCOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 25. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2018-2023 (USD MILLION)
TABLE 26. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SOFT TISSUE SARCOMA, BY REGION, 2024-2030 (USD MILLION)
TABLE 27. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 28. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 29. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 30. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 31. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 32. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 33. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CISPLATIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 34. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CISPLATIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 35. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2018-2023 (USD MILLION)
TABLE 36. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOCETAXEL, BY REGION, 2024-2030 (USD MILLION)
TABLE 37. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOXORUBICIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 38. GLOBAL SARCOMA DRUGS MARKET SIZE, BY DOXORUBICIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 39. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ETOPOSIDE, BY REGION, 2018-2023 (USD MILLION)
TABLE 40. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ETOPOSIDE, BY REGION, 2024-2030 (USD MILLION)
TABLE 41. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GEMCITABINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 42. GLOBAL SARCOMA DRUGS MARKET SIZE, BY GEMCITABINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 43. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IFOSFAMIDE, BY REGION, 2018-2023 (USD MILLION)
TABLE 44. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IFOSFAMIDE, BY REGION, 2024-2030 (USD MILLION)
TABLE 45. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PACLITAXEL, BY REGION, 2018-2023 (USD MILLION)
TABLE 46. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PACLITAXEL, BY REGION, 2024-2030 (USD MILLION)
TABLE 47. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TRABECTEDIN, BY REGION, 2018-2023 (USD MILLION)
TABLE 48. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TRABECTEDIN, BY REGION, 2024-2030 (USD MILLION)
TABLE 49. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VINCRISTINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 50. GLOBAL SARCOMA DRUGS MARKET SIZE, BY VINCRISTINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 51. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2018-2023 (USD MILLION)
TABLE 52. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, BY REGION, 2024-2030 (USD MILLION)
TABLE 53. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 54. GLOBAL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 55. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2018-2023 (USD MILLION)
TABLE 56. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ATEZOLIZUMAB, BY REGION, 2024-2030 (USD MILLION)
TABLE 57. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2023 (USD MILLION)
TABLE 58. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2024-2030 (USD MILLION)
TABLE 59. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, BY REGION, 2018-2023 (USD MILLION)
TABLE 60. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, BY REGION, 2024-2030 (USD MILLION)
TABLE 61. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 62. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 63. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ENTRECTINIB, BY REGION, 2018-2023 (USD MILLION)
TABLE 64. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ENTRECTINIB, BY REGION, 2024-2030 (USD MILLION)
TABLE 65. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PAZOPANIB, BY REGION, 2018-2023 (USD MILLION)
TABLE 66. GLOBAL SARCOMA DRUGS MARKET SIZE, BY PAZOPANIB, BY REGION, 2024-2030 (USD MILLION)
TABLE 67. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SORAFENIB, BY REGION, 2018-2023 (USD MILLION)
TABLE 68. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SORAFENIB, BY REGION, 2024-2030 (USD MILLION)
TABLE 69. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUNITINIB, BY REGION, 2018-2023 (USD MILLION)
TABLE 70. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SUNITINIB, BY REGION, 2024-2030 (USD MILLION)
TABLE 71. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TAZEMETOSTAT, BY REGION, 2018-2023 (USD MILLION)
TABLE 72. GLOBAL SARCOMA DRUGS MARKET SIZE, BY TAZEMETOSTAT, BY REGION, 2024-2030 (USD MILLION)
TABLE 73. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 74. GLOBAL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 75. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 76. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 77. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 78. GLOBAL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 79. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 80. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITALS PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 81. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2023 (USD MILLION)
TABLE 82. GLOBAL SARCOMA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2024-2030 (USD MILLION)
TABLE 83. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2023 (USD MILLION)
TABLE 84. GLOBAL SARCOMA DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2024-2030 (USD MILLION)
TABLE 85. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 86. GLOBAL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 87. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2018-2023 (USD MILLION)
TABLE 88. GLOBAL SARCOMA DRUGS MARKET SIZE, BY CANCER RESEARCH CENTER, BY REGION, 2024-2030 (USD MILLION)
TABLE 89. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
TABLE 90. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
TABLE 91. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2018-2023 (USD MILLION)
TABLE 92. GLOBAL SARCOMA DRUGS MARKET SIZE, BY HOSPITAL & CLINICS, BY REGION, 2024-2030 (USD MILLION)
TABLE 93. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 94. AMERICAS SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 95. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 96. AMERICAS SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 97. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 98. AMERICAS SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 99. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 100. AMERICAS SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 101. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 102. AMERICAS SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 103. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 104. AMERICAS SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 105. AMERICAS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 106. AMERICAS SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 107. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 108. AMERICAS SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 109. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 110. AMERICAS SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 111. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 112. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 113. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 114. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 115. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 116. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 117. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 118. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 119. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 120. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 121. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 122. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 123. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 124. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 125. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 126. ARGENTINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 127. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 128. BRAZIL SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 129. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 130. BRAZIL SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 131. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 132. BRAZIL SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 133. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 134. BRAZIL SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 135. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 136. BRAZIL SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 137. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 138. BRAZIL SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 139. BRAZIL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 140. BRAZIL SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 141. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 142. BRAZIL SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 143. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 144. CANADA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 145. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 146. CANADA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 147. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 148. CANADA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 149. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 150. CANADA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 151. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 152. CANADA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 153. CANADA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 154. CANADA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 155. CANADA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 156. CANADA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 157. CANADA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 158. CANADA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 159. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 160. MEXICO SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 161. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 162. MEXICO SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 163. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 164. MEXICO SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 165. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 166. MEXICO SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 167. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 168. MEXICO SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 169. MEXICO SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 170. MEXICO SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 171. MEXICO SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 172. MEXICO SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 173. MEXICO SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 174. MEXICO SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 175. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 176. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 177. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 178. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 179. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 180. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 181. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 182. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 183. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 184. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 185. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 186. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 187. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 188. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 189. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 190. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 191. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 192. UNITED STATES SARCOMA DRUGS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 193. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 194. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 195. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 196. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 198. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 200. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 202. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 204. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 206. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 208. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 210. ASIA-PACIFIC SARCOMA DRUGS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 211. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 212. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 213. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 214. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 215. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 216. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 217. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 218. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 219. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 220. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 221. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 222. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 223. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 224. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 225. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 226. AUSTRALIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 227. CHINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 228. CHINA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 229. CHINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 230. CHINA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 231. CHINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 232. CHINA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 233. CHINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 234. CHINA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 235. CHINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 236. CHINA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 237. CHINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 238. CHINA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 239. CHINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 240. CHINA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 241. CHINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 242. CHINA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 243. INDIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 244. INDIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 245. INDIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 246. INDIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 247. INDIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 248. INDIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 249. INDIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 250. INDIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 251. INDIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 252. INDIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 253. INDIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 254. INDIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 255. INDIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 256. INDIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 257. INDIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 258. INDIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 259. INDONESIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 260. INDONESIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 261. INDONESIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 262. INDONESIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 263. INDONESIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 264. INDONESIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 265. INDONESIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 266. INDONESIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 267. INDONESIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 268. INDONESIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 269. INDONESIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 270. INDONESIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 271. INDONESIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 272. INDONESIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 273. INDONESIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 274. INDONESIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 275. JAPAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 276. JAPAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 277. JAPAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 278. JAPAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 279. JAPAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 280. JAPAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 281. JAPAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 282. JAPAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 283. JAPAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 284. JAPAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 285. JAPAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 286. JAPAN SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 287. JAPAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 288. JAPAN SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 289. JAPAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 290. JAPAN SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 291. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 292. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 293. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 294. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 295. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 296. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 297. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 298. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 299. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 300. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 301. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 302. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 303. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 304. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 305. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 306. MALAYSIA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 307. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 308. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 309. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 310. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 311. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 312. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 313. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 314. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 315. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 316. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 317. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 318. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 319. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 320. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 321. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 322. PHILIPPINES SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 323. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 324. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 325. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 326. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 327. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 328. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 329. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 330. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 331. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 332. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 333. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 334. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 335. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 336. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 337. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 338. SINGAPORE SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 339. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 340. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 341. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 342. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 343. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 344. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 345. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 346. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 347. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 348. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 349. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2018-2023 (USD MILLION)
TABLE 350. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY SALES CHANNEL, 2024-2030 (USD MILLION)
TABLE 351. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2018-2023 (USD MILLION)
TABLE 352. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY OFFLINE, 2024-2030 (USD MILLION)
TABLE 353. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
TABLE 354. SOUTH KOREA SARCOMA DRUGS MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
TABLE 355. TAIWAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 356. TAIWAN SARCOMA DRUGS MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 357. TAIWAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2018-2023 (USD MILLION)
TABLE 358. TAIWAN SARCOMA DRUGS MARKET SIZE, BY DRUGS, 2024-2030 (USD MILLION)
TABLE 359. TAIWAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 360. TAIWAN SARCOMA DRUGS MARKET SIZE, BY CHEMOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 361. TAIWAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2018-2023 (USD MILLION)
TABLE 362. TAIWAN SARCOMA DRUGS MARKET SIZE, BY IMMUNOTHERAPY DRUGS, 2024-2030 (USD MILLION)
TABLE 363. TAIWAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2018-2023 (USD MILLION)
TABLE 364. TAIWAN SARCOMA DRUGS MARKET SIZE, BY TARGETED DRUG THERAPY, 2024-2030 (USD MILLION)
TABLE 365. TAIWAN SARCOMA DRUGS MARK

Companies Mentioned

  • Abbott Laboratories
  • AbbVie Inc.
  • AgonOx
  • Amneal Pharmaceuticals LLC
  • Aurobindo Pharma Limited
  • Avacta Life Sciences Limited
  • Baxter International Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Fresenius SE & Co. KGaA
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • TRACON Pharmaceuticals, Inc.
  • Viatris Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 1.66 Billion
Forecasted Market Value ( USD ) by 2030 $ 2.66 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned27

Related Topics

Related Reports

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 93 Pages
  • Global
From
Sarcoma Drugs Global Market Report 2024 - Product Image

Sarcoma Drugs Global Market Report 2024

  • Report
  • 200 Pages
  • Global
From
Sarcoma Drugs - Global Strategic Business Report - Product Image

Sarcoma Drugs - Global Strategic Business Report

  • Report
  • 93 Pages
  • Global
From
Sarcoma Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Sarcoma Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 170 Pages
  • Global
From
Ewing Sarcoma Drugs Market - Global Ewing Sarcoma Drugs Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 - Product Image

Ewing Sarcoma Drugs Market - Global Ewing Sarcoma Drugs Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030

  • Report
  • 280 Pages
  • Global

About the Sarcoma Drug Market

Sarcoma is a type of cancer that affects the connective tissues of the body, such as muscle, bone, fat, and blood vessels. Sarcoma drugs are used to treat this type of cancer, and are part of the larger oncology drug market. These drugs are typically used in combination with other treatments, such as surgery, radiation, and chemotherapy. Sarcoma drugs are designed to target the specific type of cancer, and can be used to reduce the size of tumors, slow the growth of cancer cells, and reduce the risk of metastasis. The sarcoma drug market is highly competitive, with many companies developing new treatments and therapies. Some of the major players in the market include Pfizer, Merck, Novartis, Bristol-Myers Squibb, and Eli Lilly. Other companies, such as Amgen, AstraZeneca, and Celgene, are also developing treatments for sarcoma. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.